Bicycle Therapeutics (NASDAQ:BCYC) Raised to “Strong-Buy” at Jefferies Financial Group

Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by analysts at Jefferies Financial Group to a “strong-buy” rating in a research report issued on Tuesday,Zacks.com reports.

A number of other research analysts have also commented on BCYC. Citizens Jmp set a $12.00 price objective on shares of Bicycle Therapeutics in a research report on Friday, October 31st. Truist Financial started coverage on Bicycle Therapeutics in a report on Monday, November 24th. They set a “hold” rating and a $10.00 price objective on the stock. Citigroup restated an “outperform” rating on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Royal Bank Of Canada restated a “sector perform” rating and issued a $11.00 price objective (down previously from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Bicycle Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.11.

Bicycle Therapeutics Trading Up 2.9%

BCYC opened at $5.38 on Tuesday. The business has a 50 day moving average of $6.52 and a 200-day moving average of $7.07. The stock has a market capitalization of $373.21 million, a price-to-earnings ratio of -1.49 and a beta of 1.63. Bicycle Therapeutics has a 1-year low of $5.03 and a 1-year high of $12.60.

Insider Buying and Selling

In other Bicycle Therapeutics news, CFO Alethia Young sold 4,334 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $6.49, for a total transaction of $28,127.66. Following the transaction, the chief financial officer owned 87,081 shares of the company’s stock, valued at approximately $565,155.69. This represents a 4.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin Lee sold 10,989 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.46, for a total value of $70,988.94. Following the transaction, the chief executive officer directly owned 618,996 shares in the company, valued at $3,998,714.16. This trade represents a 1.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 38,029 shares of company stock valued at $251,966. 22.90% of the stock is currently owned by company insiders.

Institutional Trading of Bicycle Therapeutics

Several hedge funds have recently bought and sold shares of BCYC. Assetmark Inc. boosted its stake in Bicycle Therapeutics by 74.9% in the 3rd quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after purchasing an additional 1,552 shares during the period. Clearstead Advisors LLC raised its stake in Bicycle Therapeutics by 234.2% in the fourth quarter. Clearstead Advisors LLC now owns 4,655 shares of the company’s stock valued at $33,000 after buying an additional 3,262 shares during the period. Brooklyn Investment Group acquired a new stake in Bicycle Therapeutics during the 4th quarter valued at $69,000. Ausdal Financial Partners Inc. acquired a new stake in Bicycle Therapeutics during the second quarter worth approximately $70,000. Finally, Pinnacle Wealth Management Advisory Group LLC acquired a new stake in shares of Bicycle Therapeutics during the fourth quarter worth $71,000. 86.15% of the stock is currently owned by institutional investors and hedge funds.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.